Clene Inc. Advances Toward FDA Approval for ALS Treatment CNM-Au8®
July 28th, 2025 1:05 PM
By: Newsworthy Staff
Clene Inc. is making significant progress toward FDA accelerated approval for its ALS drug CNM-Au8®, targeting a $1.3 billion market by 2034 with a novel approach to neurodegenerative diseases.
Clene Inc. (NASDAQ: CLNN) is on a promising path toward securing FDA accelerated approval for its lead drug candidate, CNM-Au8®, aimed at treating Amyotrophic Lateral Sclerosis (ALS), a market projected to reach $1.3 billion by 2034. The company's innovative approach focuses on addressing mitochondrial dysfunction, a key factor in neurodegenerative diseases, with pivotal FDA meetings anticipated in 2025 that could significantly influence its valuation.
The regulatory case for CNM-Au8® will heavily rely on biomarker and survival data from over 150 patients, with crucial NfL data expected in the fourth quarter of 2025. Clene is also gearing up to launch a confirmatory Phase 3 ALS trial in the first half of 2026, alongside advancing a separate program for multiple sclerosis (MS) into late-stage development.
CNM-Au8® represents a unique oral treatment option for ALS, designed to enhance mitochondrial function and protect neurons. This differentiated mechanism of action positions Clene to capture a substantial share of the growing ALS treatment market. Investors are encouraged to consider Clene's potential in addressing the significant unmet needs within the biopharmaceutical sector, particularly in underserved markets like ALS and MS.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
